Neoplasms

Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS

Retrieved on: 
Thursday, November 19, 2020

The oral presentation given by Dr. Brian Van Tine of the Washington University School of Medicine is available on-demand for congress attendees.

Key Points: 
  • The oral presentation given by Dr. Brian Van Tine of the Washington University School of Medicine is available on-demand for congress attendees.
  • Dr. Van Tine will also participate in a live stream session entitled - Immunotherapy in Sarcoma: Alveolar Soft Part Sarcoma, Clear Cell Sarcoma, Synovial Sarcoma (Proffered Papers Panel Discussion) scheduled for 9 AM EST today (November 19).
  • The impact on patients treated with ADP-A2M4 is transformative, as they benefit from a durable response from a single treatment.
  • Data presented at CTOS were updated durability of response and safety data from the 16patients with synovial sarcoma who were treated in the Phase 1 ADP-A2M4 trial, presented earlier this year at ASCO.

"Because of Miracle Flights, He Still Has His Eyes": 2-Year-Old Battling Rare Cancer Boards 15th Miracle Flight to Cure

Retrieved on: 
Wednesday, November 18, 2020

Jude was officially diagnosed with retinoblastoma, a rare eye cancer that primarily affects children under 5.

Key Points: 
  • Jude was officially diagnosed with retinoblastoma, a rare eye cancer that primarily affects children under 5.
  • If the Stephens family wanted to follow her, she knew of an organization that would fly them there for free: Miracle Flights.
  • Aubrey and Jude boarded their first Miracle Flight on July 18, 2019, and have flown every four to six weeks since.
  • To help Jude continue his journey to beat canceror to request a Miracle Flight for your familyvisit miracleflights.org.

Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

Retrieved on: 
Monday, November 9, 2020

At the time of analysis, 123 patients with advanced cancers had been treated with cosibelimab and were evaluable for safety.

Key Points: 
  • At the time of analysis, 123 patients with advanced cancers had been treated with cosibelimab and were evaluable for safety.
  • Cosibelimab appeared to be safe and well-tolerated with a potentially favorable safety profile as compared to anti-PD-1 therapies currently available.
  • A copy of the poster presentation is available on the Publications page of the Pipeline section of Checkpoints website, www.checkpointtx.com .
  • According to the American Cancer Society, it is estimated that more than 228,000 Americans will be diagnosed with lung cancer in 2020, and non-small cell lung cancer accounts for 80-85% of all lung cancers.

FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue Sarcoma

Retrieved on: 
Thursday, October 29, 2020

CRANBURY, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (Rafael or the Company), a leader in the growing field of cancer metabolism-based therapeutics announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for CPI-613 (devimistat) for the treatment of soft tissue sarcoma.

Key Points: 
  • CRANBURY, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (Rafael or the Company), a leader in the growing field of cancer metabolism-based therapeutics announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for CPI-613 (devimistat) for the treatment of soft tissue sarcoma.
  • There are more than 50 different types of soft tissue sarcomas, and clear cell is ranked among the rarest .
  • There is a significant unmet need in treatment for soft tissue sarcoma, said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals.
  • In fact, Rafael is one of the only companies working on a treatment for clear cell sarcoma.

Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, October 29, 2020

We are very pleased to receive FDAs conditional acceptance of our proprietary name, REQORSA, which is a necessary step toward being able to market our lead drug candidate for non-small cell lung cancer, said Rodney Varner, President and Chief Executive Officer of Genprex.

Key Points: 
  • We are very pleased to receive FDAs conditional acceptance of our proprietary name, REQORSA, which is a necessary step toward being able to market our lead drug candidate for non-small cell lung cancer, said Rodney Varner, President and Chief Executive Officer of Genprex.
  • Final approval of the REQORSA brand name is conditional on FDA approval of the product candidate.
  • In January 2020, the FDA granted Fast Track Designation for REQORSA in combination with AstraZenecas Tagrisso for the treatment of non-small cell lung cancer.
  • The Companys lead product candidate, REQORSA immunogene therapy drug (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC).

Global Osteosarcoma Market to 2030 - Insights, Epidemiology and Forecast - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 28, 2020

The "Osteosarcoma - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Osteosarcoma - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Osteosarcoma market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Osteosarcoma market size from 2017 to 2030.
  • The Report also covers current Osteosarcoma treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
  • To understand the future market competition in the Osteosarcoma market and Insightful review of the key market drivers and barriers.

Actress Marcia Cross Launches Non-Profit Organization After Successful Battle with Cancer

Retrieved on: 
Tuesday, October 20, 2020

NEW YORK, Oct. 20, 2020 /PRNewswire/ --After a successful battle with cancer, actress Marcia Cross has launched non-profit organization HPV Alliance and a second career as a health advocate.

Key Points: 
  • NEW YORK, Oct. 20, 2020 /PRNewswire/ --After a successful battle with cancer, actress Marcia Cross has launched non-profit organization HPV Alliance and a second career as a health advocate.
  • In 2019, the actress went public about her cancer diagnosis and recovery.
  • As survivors of HPV-associated cancer, Ms. Cross and Ms. Kreppel saw a need to de-stigmatize Human Papillomavirus (HPV) and shed light on the seven types of cancer that have been found to be caused by this infection.
  • To schedule an interview with a member of the HPV Alliance team and learn more about the organization, please contact Media Tonic .

Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat Glioblastoma

Retrieved on: 
Friday, October 16, 2020

Paul Michaels, Chairman and President of CTYX said,We are pleased to have added this cutting-edge technology to our development portfolio.

Key Points: 
  • Paul Michaels, Chairman and President of CTYX said,We are pleased to have added this cutting-edge technology to our development portfolio.
  • Pediatric Glioblastoma is one of the deadliest childhood diseases with an average survival rate of less than two years.
  • About Connectyx Technologies Holdings Group, Inc. http://connectyx.com/
    Connectyx is a development-stage biomedical company focusing on novel treatments for rare diseases.
  • Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.

Savran Technologies Inc. Rare Cell Detection Platform Contributes to Successful Clinical Trial for Detecting Breast Cancer Recurrence

Retrieved on: 
Thursday, October 15, 2020
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20201015005035/en/
    The trial involved about 200 patients with early stage triple negative breast cancer who received chemotherapy and underwent surgery.
  • The study, which is the largest of its kind to date, involved using circulating biomarkers with triple negative breast cancer who had residual disease.
  • Results demonstrated that circulating markers were more successful in predicting relapse than other, more commonly used clinical markers such as tumor size, lymph node status, grade and stage.
  • Augmenting a ctDNA analysis with Savran Technologies CTC analysis platform improved the sensitivity of predicting relapse to 90%.

Global Kaposi's Sarcoma Market and Competitive Landscape Report 2020: Pipeline, Epidemiology, Forecasts, Sales & Competitive Landscape 2016-2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 12, 2020

The "Global Kaposi's Sarcoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Kaposi's Sarcoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Global Kaposi's Sarcoma Market and Competitive Landscape - 2020, provides comprehensive insights into the Kaposi's Sarcoma pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Kaposi's Sarcoma market size and drug sales.
  • Kaposi's Sarcoma pipeline: Find out drugs in clinical trials for the treatment of Kaposi's Sarcoma by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Kaposi's Sarcoma drugs: Identify key drugs marketed and prescribed for Kaposi's Sarcoma in the US, including trade name, molecule name, and company
    Kaposi's Sarcoma market valuations: Find out the market size for Kaposi's Sarcoma drugs in 2019 by countries.